<DOC>
	<DOCNO>NCT02609659</DOCNO>
	<brief_summary>This study seek assess safety efficacy treatment ombitasvir/paritaprevir/ritonavir dasabuvir ribavirin non-cirrhotic , genotype 1a ( GT1a ) hepatitis C virus infect participant treatment-naïve treatment-experienced Interferon ( IFN ) Pegylated Interferon ( pegIFN ) without Ribavirin ( RBV ) .</brief_summary>
	<brief_title>Ombitasvir/Paritaprevir/Ritonavir Dasabuvir With Low-Dose Ribavirin QD Subjects With Genotype 1a Chronic Hepatitis C Virus Infection</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<criteria>Chronic HCV infection Noncirrhotic subject Screening laboratory result show HCV Genotype 1a infection HCV treatmentnaïve treat previously , IFN pegINF without RBV Pregnant breastfeed woman Positive hepatitis B surface antigen ( HBsAg ) antihuman immunodeficiency virus antibody ( HIV Ab ) HCV genotype subtype 1a unable subtype Prior current use investigational commercially available antiHCV agent IFN , pegIFN RBV . Subjects previous participation trial investigational directacting antiviral agent ( DAAs ) may enrol produce documentation receive placebo . Current enrollment another interventional clinical study receipt investigational product within 6 week prior study drug administration .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Chronic Hepatitis C Infection</keyword>
</DOC>